Read our Recent Headlines

Dave-Trading Alert – CELG

I was still not exercised, but it looks like tonight our CELG options will be exercised. Monday, we will be selling the February $120 calls. We will have 200 CELG.

January 20th Biotech Update

We are getting some more offerings as is expected post JPM but they seem slower than usual. In any case, we have more large cap pharma news that is pretty.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 1

The following was a research project completed for my Economics of Regulation class about tax inversions, the implications, and proposed solutions.  Since this is a large paper, it will be.

January 18 Biotech Update

We have some news to talk about that seems to be a net neutral but in terms of individual stocks are likely meaningful. I also do not want to beat.

January 17 Biotech Update

The sector appears to have shrugged off (relatively speaking as to what could have happened) the recent Trump noise on the industry and likely for good reason. It is only.

January 13 Biotech Update

JPM is over and I am back. It is a lot to digest, so I will do some broad highlights today and then get more into details on Monday. To.

January 9 Biotech Update

I am getting ready to head out to JPM but I wanted to have a quick JPM note this morning. In general, the news has been a little slow as.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!